To bridge the gap from discovery to delivery, biotechs must design rigorous, scalable translational strategies that optimise developability, maintain strict quality control and ensure regulatory alignment from the very first screening.
Here, Himanshu Gadgil PhD, Chief Executive Officer of Enzene, discusses his advice for biotech innovators seeking to achieve scalable molecules and avoid common, expensive mistakes from the start.
He talks about avoiding the single most expensive mistake biotechs make during technology transfer, to ensuring that ‘Disneyland’ molecule in discovery is scalable and successful throughout the process.
